UT MD ANDERSON CANCER CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $2.3B
- Transactions
- 47,242
- Companies
- 40
- Average per transaction
- $47,863
Who reported the payments
| Takeda Pharmaceuticals U.S.A., Inc. | $485,223,153 |
| AstraZeneca | $232,557,049 |
| E.r. Squibb & Sons, L.L.C. | $180,690,306 |
| Merck | $148,383,490 |
| Amgen | $143,042,500 |
| Pfizer | $121,778,927 |
| AbbVie | $103,823,397 |
| Novartis | $78,511,221 |
| Pharmacyclics LLC, An Abbvie Company | $51,405,527 |
| Servier Bioinnovation | $43,352,040 |
| Genentech, Inc. | $42,406,931 |
| Seagen Inc. | $30,473,019 |
| Eli Lilly | $29,881,450 |
| Bristol Myers Squibb | $29,090,840 |
| Beigene, Ltd. | $28,558,367 |
| Janssen Research & Development, LLC | $27,273,652 |
| Regeneron | $25,882,776 |
| Jazz Pharmaceuticals Inc. | $23,709,383 |
| Daiichi Sankyo Inc. | $22,822,852 |
| Sanofi US Services Inc. | $22,006,785 |
| Taiho Oncology, Inc. | $20,341,966 |
| Incyte Corporation | $20,308,345 |
| Gilead | $19,596,109 |
| Siemens Medical Solutions USA, Inc. | $19,427,526 |
| Bayer | $19,289,103 |
| Servier Pharmaceuticals LLC | $16,063,553 |
| Deciphera Pharmaceuticals Inc. | $15,374,698 |
| Mirati Therapeutics, Inc. | $12,395,671 |
| Astrazeneca UK Limited | $11,998,621 |
| Astellas Pharma Inc | $10,385,071 |
| Blueprint Medicines Corporation | $9,992,211 |
| Ipsen Bioscience Inc. | $9,036,114 |
| Boehringer Ingelheim | $8,518,417 |
| Daiichi Sankyo Company LTD | $8,467,939 |
| Otsuka Pharmaceutical Co., Ltd. | $7,677,770 |
| GE HealthCare | $7,382,887 |
| Abbott | $6,097,207 |
| Exelixis Inc. | $5,960,414 |
| Philips North America LLC | $5,914,354 |
| Rigel Pharmaceuticals, Inc. | $5,679,006 |